-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Graft-versus-host disease (GVHD) remains the leading cause of post-transplantation mortality and morbidity after allogeneic hematopoietic cell transplantation (alloHCT), adding a huge economic burden and affecting quality of life, thus, in patients with no increased risk of relapse.
In this study, researchers tested a new conditioning regimen, total bone marrow and lymphoid irradiation (TMLI) at 2000 cGy and post-transplant cyclophosphamide (PTCy) for the first or second CR.
2000 cGy of total bone marrow and lymphoid irradiation (TMLI) and post-transplant cyclophosphamide (PTCy) are used in acute myeloid leukemia patients with first or second CR to reduce the risk of chronic GVHD by using PTCy while at the same time.
Patient safety lead-in was performed first to ensure no unexpected toxicities, and expanded in the absence of dose-limiting toxicities (DLT)
Figure 1: Treatment regimen
Figure 1: Treatment regimen
Figure 2: Acute GVHD, Chronic GVHD and GRFS
Figure 2: Acute GVHD, Chronic GVHD and GRFSFigure 3: Progression-Free Survival, Overall Survival, Relapse-Free Survival, and Relapse-Free Mortality
Figure 3: Progression-Free Survival, Overall Survival, Relapse-Free Survival, and Relapse-Free MortalityThe results suggest that among 18 patients with a median age of 40 years (range 19-56 years), the highest-grade toxicities were Grade 2 Bearman's bladder toxicity and stomatitis
Overall, this chemotherapy-free conditioning regimen, along with PTCy and tacrolimus, was safe with no non-relapse mortality (NRM), and preliminary results suggest an improvement in GRFS rates
This chemotherapy-free conditioning regimen, along with PTCy and tacrolimus, is safe with no non-relapse mortality (NRM), and preliminary results suggest improved GRFS rates
Original source:
Original source:Stein AS, Malki MMA, Yang D, Palmer JM, Tsai NC, Aldoss I, Ali H, Aribi A, Artz A, Dandapani S, Farol L, Hui S, Liu A, Nakamura R, Pullarkat V, Radany E, Rosenthal J , Salhotra A, Sanchez JF, Spielberger R, Marcucci G, Forman SJ, Wong J.
Stein AS, Malki MMA, Yang D, Palmer JM, Tsai NC, Aldoss I, Ali H, Aribi A, Artz A, Dandapani S, Farol L, Hui S, Liu A, Nakamura R, Pullarkat V, Radany E, Rosenthal J , Salhotra A, Sanchez JF, Spielberger R, Marcucci G, Forman SJ, Wong J.
Total Marrow and Lymphoid Irradiation with Post-Transplant Cyclophosphamide for Patients with AML in Remission.
Transplant Cell Ther.
2022 Apr 6:S2666-6367(22) 01190-3.
doi: 10.
1016/j.
jtct.
2022.
03.
025.
Epub ahead of print.
PMID: 35398328.
Stein AS, Malki MMA, Yang D, Palmer JM, Tsai NC, Aldoss I, Ali H, Aribi A, Artz A, Dandapani S, Farol L, Hui S, Liu A, Nakamura R, Pullarkat V, Radany E, Rosenthal J , Salhotra A, Sanchez JF, Spielberger R, Marcucci G, Forman SJ, Wong J.
Total Marrow and Lymphoid Irradiation with Post-Transplant Cyclophosphamide for Patients with AML in Remission.
Transplant Cell Ther.
2022 Apr 6:S2666-6367(22) 01190-3.
doi: 10.
1016/j.
jtct.
2022.
03.
025.
Epub ahead of print.
PMID: 35398328.
Leave a message here
